Apr 02 2009
PSA screening delivers a 20% reduction in mortality from prostate cancer
Screening for prostate cancer can reduce deaths by 20%, according to the results of the European Randomized Study of Screening for Prostate Cancer (ERSPC) published online in at NEJM, Online First.
ERSPC is the world’s largest prostate cancer screening study and provides robust, independently audited evidence, for the first time, of the effect of screening on prostate cancer mortality.
The study commenced Continue Reading »